- This event has passed.
第 11 屆年度 ECD 醫學研討會 – 伯明翰 2026

埃爾德海姆-切斯特病全球聯盟宣布 2026 年醫學研討會
阿拉巴馬州伯明翰 — 埃德海姆-切斯特病全球聯盟 (ECDGA) 和 UAB 醫學院邀請醫療保健專業人員和研究人員。
- 醫學研討會:2026 年 4 月 30 日至 5 月 2 日
2026 年 4 月 30 日(星期四)
病友與家屬聚會:上午 8:00 – 下午 4:30
地點:阿拉巴馬大學伯明翰分校 Marnix E. Heersink 會議中心
慶祝晚宴:下午 6:00 – 晚上 8:00
地點:Hilton at UAB Downtown
2026 年 5 月 1 日,星期五
醫學研討會:上午 8:00 – 下午 5:00
地點:阿拉巴馬大學伯明翰分校 Marnix E. Heersink 會議中心
醫學研討會招待晚會:下午 6:00 – 晚上 8:00
地點:阿拉巴馬大學伯明翰分校 Marnix E. Heersink 會議中心
2026 年 5 月 2 日,星期六
ECD 照護中心會議:上午 8:00 – 上午 11:00
地點:UAB 癌症中心
本次活動將匯集全球埃爾德海姆-切斯特病界與領先的醫學專家,分享最新研究、臨床見解和社區資源。 與會者可以期待教育課程、與同行聯繫的機會以及新興治療和患者護理的最新信息。
有關酒店和節目亮點的更多詳細信息將在未來幾個月內發布。
議程
| Time | Subject | Presenter |
|---|---|---|
| 8:00 am | Registration & light breakfast | |
| 8:30 am | Welcome to Birmingham and the 11th Annual Erdheim-Chester Disease International Conference | Gaurav Goyal University of Alabama at Birmingham, Birmingham, AL USA |
| Keynote Address | ||
| 8:45 am | Diversity and Degeneration in Neurohistiocytic Disease | Nicole Coufal University of California, San Diego USA |
| 9:25 am | Break | |
| Morning Abstract Presentations Session 1: Cells, Clones & Circuits: Where Histiocytosis Begins (and Persists) | ||
| 9:35 am | ARAF Mutations Drive Histiocytic Neoplasms In Vivo and Provide Insights into Cellular Origin | Benjamin Durham Rutgers Cancer Institute, Robert Wood Johnson School of Medicine, Brunswick, NJ |
| 9:50 am | Tracking BRAF V600E Persistence under MEK Inhibition in Histiocytoses: a B-cell–enriched signal | Julien Haroche Department of Internal Medicine & E3M Institute, Pitié-Salpêtrière Hospital, AP-HP – Sorbonne University, Paris, France |
| 10:05 am | Distribution of MAP2K1 Variants Across Peripheral Blood Cells in Erdheim-Chester Disease and Other Histiocytoses | Irena Ungureanu Ambroise-Paré Hospital, Pathology Department, Boulogne-Billancourt, France |
| 10:20 am | The Clonal Origin and Evolution of High-Risk Multisystem Histiocytosis in Adults | Matthew Collin Newcastle University, United Kingdom |
| 10:35 am | Networking Break | |
| Morning Abstract Presentations Session 2: Genotype → Therapy: Biomarkers, Responses, and New Vulnerabilities | ||
| 10:50 am | KRAS Mutations in Histiocytic Neoplasms: Mutation Spectrum and Response to MEK Inhibition | Dongni Yi Mayo Clinic, Rochester, MN USA |
| 11:05 am | Cyclin D1 Overexpression Drives Replication Stress and Creates Therapeutic Vulnerabilities in Histiocytic Neoplasms | Dongni Yi Mayo Clinic, Rochester, MN USA |
| 11:20 am | Clonal Hematopoiesis Predicts Response to Interferon-α in Erdheim-Chester Disease and Myeloproliferative Neoplasms | Jérôme Razanamahery Dijon University Hospital, France |
| 11:35 am | Impact of Additional Genetic Variants in the Course of Erdheim-Chester Disease… a Multicentric Longitudinal Study of 445 French Patients | Félicien Triboulet Pitié-Salpêtrière hospital, Sorbonne University, Paris, France |
| 11:50 am | Group Photo | |
| 12:00 pm | Lunch | |
| Afternoon Abstract Presentations Session 3: Pixels to Patterns: ECD and Xanthogranuloma | ||
| 1:00 pm | Central Nervous System Imaging Abnormalities in Erdheim–Chester Disease: A Systematic Review | Mustafa Abomohsen Brookdale University Hospital and Medical Center, Brooklyn, NY USA |
| 1:15 pm | Musculoskeletal System Imaging Abnormalities in Erdheim–Chester Disease: A Systematic Review | Mustafa Abomohsen Brookdale University Hospital and Medical Center, Brooklyn, NY USA |
| 1:30 pm | Patterns of Presentation and Outcomes in Adult Xanthogranuloma | Guneet Janda Mayo Clinic, Rochester, MN USA |
| 1:45 pm | Networking Break | |
| Afternoon Abstract Presentations Session 4: Care in the Real World: Treatment Patterns and Survivorship | ||
| 2:00 pm | Real World Frontline Systemic Anti-Cancer Treatment Patterns and Outcomes in Erdheim–Chester Disease | Carla Isabel Borre Mayo Clinic, Rochester, MN USA |
| 2:15 pm | Burden of Chronic Health Conditions After Diagnosis of Erdheim–Chester Disease (ECD): Early Results from the Histiocytic Disorder Survivor Study | Gaurav Goyal University of Alabama at Birmingham, Birmingham, AL USA |
| 2:30 pm | Destombes-Rosai-Dorfman Disease: Clinical, Molecular Characteristics and Treatment Response: data from a retrospective cohort of 107 patients | Julien Haroche Department of Internal Medicine & E3M Institute, Pitié-Salpêtrière Hospital, AP-HP – Sorbonne University, Paris, France |
| 2:45 pm | Considerations for Assessment and Treatment of Neuropsychiatric Symptoms in ECD | Anneka Johnston Rush University Medical Center, Chicago IL |
| Poster Presentations and Networking | ||
| 3:00 pm | Erdheim-Chester Disease (ECD) is a Rare Histiocytic Neoplasm of Non-Langerhans Cell Histiocytosis | Abdalla Bowirrat Ariel University, Israel |
| Diagnostic challenges in mixed ErdheimChester Disease and Langerhans Cell Histiocytosis in a 54-year-old male | Sameer Andani Mofitt Cancer Center & University of South Florida |
|
| A Mycosis Fungoides-like Drug Reaction Rapidly Resolving Following Switch from BRAF Inhibitor to MEK Inhibitor Monotherapy in Erdheim-Chester Disease | Saipriya Ayyar University of Cincinnati/UC Health, Cincinnati OH |
|
| Multimodality Imaging in Erdheim–Chester Disease: Radiologic Insights from Pediatric and Adult Cases | Priyanka Naranje All India Institute of Medical Sciences, New Delhi, India |
|
| Cardiovascular System Imaging Abnormalities in Erdheim-Chester Disease: A Systematic Review | Mustafa Abomohsen Brookdale University Hospital and Medical Center, Brooklyn, NY USA |
|
| BRAF-Positive Erdheim–Chester Disease with Progressive Pulmonary and Vascular Involvement Successfully Treated with Vemurafenib: A Case Report | Hulya Yilmaz Tekinhatun Diyarbakir Gazi Yasargil Training and Research Hospital, Turkey |
|
| Concurrent Erdheim-Chester Disease and Classical Hodgkin Lymphoma with unexpected response to lymphoma-directed therapy | Rebecca Denson New York Presbyterian-Weill Cornell Medicine, New York, NY |
|
| Abdominal Imaging Abnormalities in Erdheim-Chester Disease: A Systematic Review | Mustafa Abomohsen Brookdale University Hospital and Medical Center, Brooklyn, NY USA |
|
| Prevalence and distribution of ErdheimChester Disease in the UK estimated from referral to a National Advisory Panel | Matthew Collin Newcastle University, United Kingdom |
|
| Challenging Case Study | ||
| 3:45 pm | All that glitters: retro-orbital xanthogranuloma or ECD? | Matthew Collin Newcastle University, United Kingdom |
| Challenging Case Study | ||
| 4:15 pm | The Clue Was the Blood Pressure: Atypical Erdheim–Chester Disease | Jithma Abeykoon Mayo Clinic, Rochester, MN USA |
| Closing Remarks & Student Abstract Award | ||
| 4:45 pm | ECD Global Alliance into the Future | Jerome Henson Executive Director, ECD Global Alliance, DeRidder, LA USA |
| 4:55 pm | Junior Investigator – Best Student Presentation Award | Oshrat Hershkovitz-Rokah Ariel University & Assut |
便條: 2月1日前報名,享受早鳥報名費用!節省 200 美元,註冊僅需 300 美元!
馬克·希尼意識獎和社區冠軍獎
2026 年 2 月 1 日 – 提交馬克·希尼意識獎和社區冠軍獎提名的最後一天。
- 請提交您的提名 這裡。
- 馬克·希尼意識獎。提名一名致力於通過提高醫學界對該疾病的認識來改善 ECD 患者生活的醫療專業人員。
- 社區冠軍獎。提名任何自願花時間幫助改善所有受 ECD 影響的人的生活的人(患者、護理人員、醫療專業人員、朋友等)。
口頭/海報摘要
2026 年 2 月 1 日 – 摘要截止日期。
- 5 月 1 日醫學研討會的摘要提交,可在 此處 接受 請提交摘要以進行口頭和/或海報展示。這是分享您和同事工作的絕佳機會。請讓他們知道這個機會。
旅遊獎學金
旅行援助 – 格倫·帕德尼克紀念旅行基金現已接受 2026 年 ECDGA 會議的申請。
格倫·帕德尼克 (Glenn Padnick) 在與埃德海姆-切斯特病 (ECD) 抗爭數十年的同時,過著充實而有影響力的生活。從 2011 年到 2022 年,他在 ECD 全球聯盟董事會中堅定不移地奉獻精神,始終確保患者的聲音和需求仍然是每個決策的核心。
為了紀念格倫的服務和同情心遺產,他的家人慷慨地設立了格倫·帕德尼克紀念旅行基金。該基金提供經濟援助,幫助患者、護理人員和醫療專業人員參加年度 ECD 會議,幫助那些因經濟拮据而無法參加的人。
2026 年 ECD 會議的旅行援助申請現已開放。資金有限,將優先考慮以前從未參加過該活動的個人。我們的目標是利用可用資源為盡可能多的社區成員提供這個機會。
截止報名日期: 2026 年 2 月 1 日獲獎通知:不遲於 2026 年 3 月 1 日
會議飯店與旅遊資訊
會議飯店
伯明罕希爾頓飯店
808 20th Street South
Birmingham, AL 35205
電話:+ 1 (659) 251-1934
UAB伯明罕希爾頓飯店已預訂一棟房間供會議參加者使用。
房間必須於2026年4月6日前預訂,才能領取團體票價。
如果您在預訂客房時遇到任何問題,請聯繫伯明翰市中心希爾頓酒店的 Simon Hill。他的電話號碼是 205-910-1970,電子郵件為 simon.hill@hiltoncom。
機場交通
伯明罕-沙特爾斯沃思國際機場(BHM)
伯明罕機場至飯店提供免費接駁服務,由UAB的希爾頓市中心直接提供。
使用接駁車:
- 收拾行李。
- 請致電飯店 205-933-9000 申請接駁車服務。
- 前往門 #4L,等待標示為「希爾頓」的公車。
經由亞特蘭大旅行
哈茲菲爾德-傑克森亞特蘭大國際機場(ATL)距離伯明罕約3小時車程,提供直飛多數國家的國際航班。亞特蘭大機場與伯明罕之間有接駁服務,方便經由亞特蘭大抵達的旅客使用。
㨟:
埃德海姆-切斯特病全球聯盟
電子郵件: [email protected]
我們的贊助商





